VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds

Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
You are here: IndiaNotes

Filter search : Quote Research All

Reports for search string : new launches

Emami: Worst seems over, upgrade to Accumulate
We estimate 12.1% sales CAGR and 16.8% PAT CAGR over FY18-20. The stock trades at 32.2xFY20 EPS of Rs32.1. We value the stock at 35xFY20 and arrive at a price target of Rs1125. Accumulate.
Prabhudas Lilladher, 22 Mar 2018
Buy CESC for an upside potential of ~25% with an investment horizon of 9-12 months
For the period of FY13-17, its topline and bottomline grew at a CAGR of ~17% and ~11% respectively. In Q3FY18 CESC’s standalone net sales grew by ~5% to Rs. 1706 crore, its operating profit was higher...
AUM CAPITAL, 13 Mar 2018
Bata India Q3FY18: PAT grew 81% YoY; Buy
Bata stands for Trust, Superior Quality & Credibility and it has maintained it for over more than 85 years. In the present scenario, the company has over 1290 Bata stores, sells 50 million pairs and s...
Suhani Adilabadkar, 23 Feb 2018
Crompton Greaves Consumer Electricals: Enough headroom for growth in core categories
We met the management of Crompton Greaves Consumer Electrical (Crompton) and came back convinced about the medium/long term opportunities for growth and management’s strategy/focus to capitalize on th...
Prabhudas Lilladher, 21 Feb 2018
Aurobindo Pharma: Decent 3Q, US to fuel growth; reiterate LONG
Aurobindo Pharma’s (ARBP) 3QFY18 Sales at Rs. 43.4bn grew by 11% yoy was largely in line with EE, EBITDA at Rs. 10.25bn grew 15% yoy was 3% below EE.
Equirus Securities, 15 Feb 2018
Cadila Healthcare 3QFY18 Results: High-value launches to help sustain growth momentum; maintain LONG
Cadila Healthcare’s (CDH) 3QFY18 sales at Rs 32.6bn (+41% yoy/+1 qoq) came in 5% below EE largely owing to market share losses in gLialda (partially compensated by gTamiflu).
Equirus Securities, 15 Feb 2018
Torrent Pharmaceuticals Q3FY18: Decent quarter, domestic market to lead growth; assign ADD
Torrent Pharmaceutical Limited’s (TRP) 3QFY18 sales (+3% yoy to Rs 14.8bn) came in 3% below EE, while EBITDA (+9% yoy to Rs 3.6bn) beat estimates led by gross margin expansion.
Equirus Securities, 15 Feb 2018
Tata Motors Q3FY18: Revenues jumped by 58% yoy on strong volume growth; Maintain Buy
On overall basis, we expect an improved performance from TAMO in the ensuing quarters. We have reduced the JLR volumes estimate a bit for FY18E/19E on volume concerns in the UK and the US. Maintain Bu...
LKP Securities, 09 Feb 2018
Lupin Q3FY18: Outlook Remains Weak; Maintain Hold
Lupin (LPC) continued to deliver a weak performance in 3QFY18 from all operational metrics. Its revenue, EBITDA and PAT declined by 11.3% YoY, 43.5% YoY and 65% YoY to Rs39.7bn, Rs6.9bn, Rs2.2bn, resp...
Reliance Securities, 09 Feb 2018
Cipla Q3FY18: Valuation Continues to Remain Pricey; Maintain Hold
At CMP, stock trades at PE multiples of 21.6x and 18.3x of FY19E and FY20E EPS, respectively, which appear to be expensive. Rolling over our estimates to FY20E, we maintain our HOLD recommendation on ...
Reliance Securities, 09 Feb 2018
Hero MotoCorp: Volumes witnessed a sound growth in Q3 on festive season; Buy
Volumes witnessed a sound growth in Q3 on festive season. This may continue to see so in the ensuing quarters too. Modelwise, the company is performing well on the scooters side off late. We maintain ...
LKP Securities, 07 Feb 2018
Alembic Pharmaceuticals Q3FY18:US biz surprises; assign REDUCE
Alembic Pharma’s (ALPM) 3QFY18 sales/EBITDA/earnings grew 9%/29%/51% to Rs 8.4bn/ Rs 1.87bn/Rs 1.31bn, 8%/6%/9% ahead of EE led by higher sales in the US business and API segment.
Equirus Securities, 05 Feb 2018
Auto Roundup Jan 18
January is seasonally a strong month for auto sales wherein customers who postpone their buying in December start buying again. But this year, December was exceptionally strong.
LKP Securities, 05 Feb 2018
Godrej Consumer Q3FY18: The long-term prospects remain intact; Hold
We believe for the medium to long term the company has well-placed growth drivers. The long-term prospects for the company remain intact. At the CMP of Rs1054.9/- the stock trades at a PE of ~49.1x & ...
Way2wealth, 31 Jan 2018
Ajanta Pharma Q3: Strong quarter led by outperformance in Asia, US markets: reiterate ADD
Ajanta Pharma’s (AJP) 3QFY18 sales/EBITDA/earnings grew 10%/11%/3% yoy to Rs 5.87bn/Rs 1.97bn/Rs 1.47bn, beating EE by a massive 17%/34%/39%. AJP’s domestic business grew only 4%
Equirus Securities, 31 Jan 2018
Ajanta Pharma Q3FY18: Growth Momentum to Continue in Domestic Biz; Maintain Buy
We believe that Ajanta Pharma’s long-term fundamentals continue to remain healthy driven by strong traction in the US business (post US FDA clearance to its Dahej unit) and above industry growth in do...
Reliance Securities, 30 Jan 2018
Emami: Rural recovery just the beginning of growth revival; Upside 23%
Our target price of INR 1655 implies a one-year upside of 23% and a two-year upside of 39%. Our bull case upside is 33% for one year and 53% for two years.
Motilal Oswal, 10 Jan 2018
Auto Volumes Dec 17: High growth low base
For the M&HCV segment, the high base due to the pre‐buying in Q4FY17 could restrict growth ahead in Q4FY18. We continue to prefer players with clear competitive advantages and waiting periods on...
Prabhudas Lilladher, 03 Jan 2018
Auto-Roundup December 2017
December is seasonally a weak month for auto sales wherein customers postpone their buying in order to get a new year of registration for their vehicles. Also some companies undertake maintenance ...
LKP Securities, 02 Jan 2018
Alkem Laboratories: Domestic Formulations Biz is the key growth driver; Buy
Looking ahead, we expect Alkem’s domestic formulations business to witness ~13.5% CAGR through FY17-20E driven by increasing focus on chronic and over-the-counter (OTC) segments, improving market shar...
Reliance Securities, 28 Dec 2017
View All

Intraday Tips

What are technical calls?
* SEBI certified analyst

View Stock Advice by: